Humacyte, Inc. (HUMAW) — 8-K Filings

8-K Filings (24)

• Humacyte, Inc. Files 8-K: Material Agreement and Exhibits — Dec 16, 2025 Risk: medium
  On December 16, 2025, Humacyte, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements a
• 8-K Filing — Dec 15, 2025
• Humacyte, Inc. Terminates Material Definitive Agreement — Nov 26, 2025 Risk: medium
  Humacyte, Inc. announced on November 21, 2025, the termination of a material definitive agreement. The company, previously known as Alpha Healthcare Acquisition
• Humacyte, Inc. Files 8-K on Financials — Nov 12, 2025 Risk: low
  Humacyte, Inc. filed an 8-K on November 12, 2025, reporting on its financial condition and results of operations. The filing also includes financial statements
• Humacyte, Inc. Files 8-K for Material Agreement — Oct 7, 2025 Risk: medium
  Humacyte, Inc. filed an 8-K on October 7, 2025, reporting a material definitive agreement entered into on October 6, 2025. The filing also includes Regulation F
• Humacyte Files 8-K, Nasdaq Listings Confirmed — Sep 18, 2025 Risk: low
  Humacyte, Inc. filed an 8-K on September 17, 2025, reporting its status as an emerging growth company. The filing confirms its common stock trades under the sym
• Humacyte, Inc. Files 8-K on Shareholder Votes & Financials — Jun 11, 2025 Risk: low
  Humacyte, Inc. filed an 8-K on June 10, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, formerly Alpha
• Humacyte Files 8-K: Regulation FD & Exhibits — Apr 18, 2025 Risk: low
  Humacyte, Inc. filed an 8-K on April 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific
• Humacyte, Inc. Files 8-K on Financials — Mar 28, 2025 Risk: low
  Humacyte, Inc. filed an 8-K on March 28, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and
• Humacyte, Inc. Files 8-K Report — Mar 27, 2025 Risk: low
  On March 27, 2025, Humacyte, Inc. filed an 8-K report. The filing indicates the company's legal jurisdiction is Delaware and provides its IRS Employer Identific
• Humacyte, Inc. Files Material Definitive Agreement 8-K — Mar 26, 2025 Risk: medium
  On March 25, 2025, Humacyte, Inc. filed an 8-K report detailing a material definitive agreement. The company, previously known as Alpha Healthcare Acquisition C
• Humacyte, Inc. Files 8-K Report — Mar 25, 2025 Risk: low
  On March 25, 2025, Humacyte, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material e
• Humacyte Files 8-K: Regulation FD Disclosure & Other Events — Dec 20, 2024 Risk: low
  On December 19, 2024, Humacyte, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements an
• Humacyte, Inc. Enters Material Definitive Agreement — Nov 14, 2024 Risk: medium
  Humacyte, Inc. announced on November 13, 2024, that it entered into a material definitive agreement. The company, formerly known as Alpha Healthcare Acquisition
• Humacyte, Inc. Files 8-K, Formerly Alpha Healthcare — Oct 28, 2024 Risk: low
  Humacyte, Inc. filed an 8-K on October 28, 2024, reporting other events and financial statements. The company was formerly known as Alpha Healthcare Acquisition
• Humacyte, Inc. Enters Material Definitive Agreement — Oct 7, 2024 Risk: medium
  On October 4, 2024, Humacyte, Inc. entered into a material definitive agreement. The company, formerly known as Alpha Healthcare Acquisition Corp. until July 16
• Humacyte, Inc. Enters Material Definitive Agreement — Sep 25, 2024 Risk: medium
  On September 24, 2024, Humacyte, Inc. entered into a material definitive agreement. The company, formerly known as Alpha Healthcare Acquisition Corp. until July
• Humacyte, Inc. Files 8-K — Jul 31, 2024 Risk: low
  Humacyte, Inc. filed an 8-K on July 31, 2024, reporting other events and financial statements. The company, formerly known as Alpha Healthcare Acquisition Corp.
• Humacyte Sells Subsidiary to Fresenius for $70M — Jun 13, 2024 Risk: medium
  Humacyte, Inc. announced on June 11, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Humacyte Global Holdings, Inc.,
• Humacyte Files 8-K on Financials — May 10, 2024 Risk: medium
  Humacyte, Inc. filed an 8-K on May 10, 2024, reporting on its financial condition and results of operations. The filing also includes financial statements and e
• Humacyte Files 8-K on Financials — Mar 22, 2024 Risk: low
  Humacyte, Inc. filed an 8-K on March 22, 2024, reporting on its results of operations and financial condition, and providing financial statements and exhibits.
• Humacyte, Inc. Files 8-K for Material Definitive Agreement — Mar 4, 2024 Risk: medium
  Humacyte, Inc. announced on February 29, 2024, that it entered into a material definitive agreement. The company, formerly known as Alpha Healthcare Acquisition
• Humacyte, Inc. Files 8-K — Feb 29, 2024 Risk: low
  Humacyte, Inc. filed an 8-K on February 29, 2024, reporting other events and financial statements. The company, formerly known as Alpha Healthcare Acquisition C
• Humacyte Confirms Nasdaq Listings for Common Stock (HUMA) & Warrants (HUMAW) — Feb 9, 2024 Risk: low
  On February 9, 2024, Humacyte, Inc. filed an 8-K to update its registered securities. The filing confirms that its Common Stock, with a par value of $0.0001 per

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX